ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ THUỐC KHÁNG VI RÚT TRỰC TIẾP TRÊN BỆNH NHÂN VIÊM GAN C MẠN

Abstract

Objective: Describe clinical, subclinical and therapeutic effects of direct-acting antiviral in patients with chronic hepatitis C.

Subjects and method: Describe 67 chronic hepatitis C infected patients who were examined and treated at the Tropical Disease Center, Nghean General Hospital from 01/2018 - 09/2020. Reseach design: Non-controlled intervention (defined by prospective combined with retrospective.)

Results and conclusions: The percentages of patients with enzyme ALT, AST, GGT within the normal range were 26.9%, 26.9% and 28.3%. Genotype 1 dominated (61.2%), followed by genotype 6 had23.9%, genotype 2 had 13.4% and a case with genotype 3 (1.5%). All patients had HCV RNA below the detection after 4 weeks of treatment, achieving RVR rate of 100%.The patients with a sustained viral response after 12 weeks of treatment discontinuation was 98.5%. Viral response did not differ between genotypes and treatment regimens.